Once-daily oral berotralstat for long-term prophylaxis of hereditary angioedema: The open-label extension of the APeX-2 randomized trial
Description
CONCLUSION: Berotralstat was generally well tolerated, provided rapid and sustained reductions in HAE attacks, and improved QoL over 96 weeks.